Study Objective: This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations.
Sponsor: National Cancer Institute (NCI)
Trial Contact Information: Study Coordinator: Ms. Abha Adat, [email protected], or the Principal Investigator Filip Janku, 713-563-1930, [email protected].
Requested Patient Involvement: ECD patients with BRAF V600 mutation who have not previously been treated with a BRAF- or MEK-inhibitor and are 18-years or older.
Known Centers Accepting ECD patients in the trial: MD Anderson, Houston, TX
ClinicalTrials.gov Identifier: NCT03794297